Furthermore, the TLR4 antagonist (TAK-242) and NF-κB inhibitor (PDTC) were used to inhibit the TLR4/NF-κB signaling pathway to further investigate the mechanism of SOCS2 in the pathogenesis of DN. Here, TLR4 is linked to liver dysplastic nodule.